Abstract:Aims-Granulovacuolar degeneration involves the accumulation of large, double membranebound bodies within certain neurons during the course of Alzheimer's disease and other adultonset dementias. Because of the two-layer membrane morphology, it has been proposed that the bodies are related to autophagic organelles. The aim of this study was to test this hypothesis, and determine the approximate stage at which the pathway stalled in Alzheimer's disease.Methods-Spatial colocalization of autophagic and endocytic ma… Show more
“…GVD bodies are double membrane enclosed partially digested cytoplasmic contents (Okamoto et al, 1991), suggesting an autophagic origin for the GVD. This autophagic association is further confirmed by positive immunostaining for LC3 and p62 (autophagic markers), LAMP1 (lysosome-associated membrane protein 1) and CHMP2B (charged multivesicular body protein 2B) to the GVD bodies (Funk et al, 2011;Yamazaki et al, 2010). These studies suggest that the GVD bodies are enlarged vesicles derived from autophagy and endocytosis.…”
Section: Granulovacuolar Degeneration and Autophagy-lysosomal Neuropamentioning
confidence: 51%
“…Granulovacuolar degeneration (GVD) along with plaques and tangles are the earliest described and also the most prominent histopathologic signs of AD (Anderton, 1997;Ball, 1982;Burger & Vogel, 1973;Funk et al, 2011;Okamoto et al, 1991). Granulovacuolar structures were initially reported for AD in 1911.…”
Section: Granulovacuolar Degeneration and Autophagy-lysosomal Neuropamentioning
“…GVD bodies are double membrane enclosed partially digested cytoplasmic contents (Okamoto et al, 1991), suggesting an autophagic origin for the GVD. This autophagic association is further confirmed by positive immunostaining for LC3 and p62 (autophagic markers), LAMP1 (lysosome-associated membrane protein 1) and CHMP2B (charged multivesicular body protein 2B) to the GVD bodies (Funk et al, 2011;Yamazaki et al, 2010). These studies suggest that the GVD bodies are enlarged vesicles derived from autophagy and endocytosis.…”
Section: Granulovacuolar Degeneration and Autophagy-lysosomal Neuropamentioning
confidence: 51%
“…Granulovacuolar degeneration (GVD) along with plaques and tangles are the earliest described and also the most prominent histopathologic signs of AD (Anderton, 1997;Ball, 1982;Burger & Vogel, 1973;Funk et al, 2011;Okamoto et al, 1991). Granulovacuolar structures were initially reported for AD in 1911.…”
Section: Granulovacuolar Degeneration and Autophagy-lysosomal Neuropamentioning
“…CHMP2B is expressed in all neuronal populations and colocalizes with granulovacuolar degenerationone of the pathological hallmarks in AD. 66,67 The partially deleted adjacent gene, POU1F1 (OMIM: 173110), has been reported to cause pituitary hormone deficiency and is associated with mental retardation. 68,69 CHMP2B has also been implicated in endosomal trafficking, the disruption of which could lead to neurodegeneration.…”
Section: Rare Autosomal Cnvs In Eo-fad Bv Hooli Et Almentioning
“…The truncated protein impairs the fusion of endosome with lysosomes without obvious modification of protein sorting to MVB (Urwin et al, 2010). Staining of tissue from Alzheimer disease patients with CHMP2B showed an accumulation of the protein in vesicular structures resembling GranuloVacuolar Degeneration (Yamazaki et al, 2010;Funk et al, 2011) suggestive of defective autophagic and endocytic pathways in Alzheimer disease. Thus, restoring or enhancing the lysosomal degradation and rates of autophagic protein turnover in a transgenic animal model of amyloid deposition can rescue the phenotype and decrease the amyloid burden (Yang et al, 2011).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.